A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants
Latest Information Update: 22 Jul 2024
At a glance
- Drugs NNC0113-6856 (Primary) ; NNC0113-6856 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
Most Recent Events
- 29 Mar 2023 Status changed from recruiting to completed.
- 09 Sep 2022 Status changed from not yet recruiting to recruiting.
- 06 Sep 2022 New trial record